RDUS (radiuspharm.com) Market Value to Book Value Ratio

Official company branding of Radius Recycling Inc. (RDUS)

Risks for Radius Recycling, Inc. (RDUS) are linked to scrap price volatility and a downturn in the automotive industry. The market capitalization-to-balance sheet dynamics on GURU.Markets show a sideways trend, where 1.61 reflects the latest metric level. Business revenues depend on industrial production and steel quotes, while the company maintains high operational reliability and B2B trust from its partners.

RDUS Radius Pharmaceuticals: Market Value to Book Value in the range 07/04/2022 - 07/26/2025

Financial and market metric breakdowns for Radius Recycling Inc. (RDUS)

- price and consensus price forecast:
Price Chart Radius Recycling, Inc.|RDUS - Analyst Median Target
- market capitalization data:
Market Value Radius Health|RDUS - Full Business Value
- book capitalization data:
Book Value per Share Radius Recycling|RDUS - Accounting Value of Company|Market Capitalization to Book Value Ratio radiuspharm.com|RDUS - Company Total Assets
- debt and liquidity data:
Debt to Equity Radius Recycling, Inc.|RDUS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Radius Health|RDUS - Company Total Debt|Debts to Book Capitalization Radius Health|RDUS - Company Long-Term Debts|Company Current Liabilities Radius Recycling
Initial company analysis:Radius Recycling, Inc. - RDUS
Original product of Radius Health

This ratio determines the market premium over the company's net assets. An analysis of the price-to-book value multiple allows for an assessment of the gap between book value and market valuation. An increase in this indicator signals either inflated investor expectations or high intangible asset value. For Radius Recycling, Inc. (RDUS), this reflects the capitalization of intellectual potential in the development of innovative osteoporosis drugs. The premium confirms market confidence in the commercial success of new therapy forms.

Main competitors

Ascendis Pharma A/S - Market Value to Book Value Ratio|MDGL (madrigalpharma.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|MiMedx (MDXG) - Market Cap to Net Assets Ratio|Market Value to Book Value RZLT (Rezolute Inc)|Lexicon Pharma - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio MBX Corp MBX|ALT (Altimmune, Inc.) - Market Capitalization to Book Value Ratio|aardvarktherapeutics.com (AARD) - Market-to-Book Ratio|SGMT - Market Cap to Net Assets Ratio|BioAge Labs (BIOA) - Market Cap to Book Value Multiple|BMEA (Biomea) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Quince|Market Capitalization to Book Value Ratio Fractyl Health, Inc. (GUTS)|Market Value to Book Value Ratio VTVT (vtvtherapeutics.com)|ATPC: Market Value to Book Value Ratio|Pluristem Therapeutics - Market-to-Book Ratio|SYBX - Market Value to Book Value Ratio|LPCN - Market Value to Book Value Ratio|matinasbiopharma.com - Market Capitalization to Book Value Ratio|SPRB (sprucebiosciences.com) - Market Capitalization to Book Value|GLTO: Market Value to Book Value Ratio|Market Capitalization to Book Value CTCX|Market Value to Book Value Ratio LUMO (Lumos Pharma Corp)|Market Cap to Net Assets Ratio ONVO (Organovo Corp)